食物アレルギーの世界市場：2024年～2031年

概要

食物アレルギーの世界市場は、2023年に401億6,000万米ドルに達し、2031年には601億9,000万米ドルに達すると予測され、予測期間2024年～2031年のCAGRは5.19%で成長する見込みです。

世界アレルギー機関は、食物アレルギーの発生率が世界的に増加していることを記録しています。卵、牛乳、小麦、魚、木の実は、最も一般的なアレルギーのひとつです。特に、魚介類アレルギーは欧米諸国よりもアジアでより多くみられます。市場の成長は、意識の高まり、満たされない医療需要、新規製品の発売に関連しています。

精製血液アッセイ、皮膚プリックテスト、分子診断などの高度な診断技術は、精度と迅速性を高めることでアレルギーの特定を促進します。食物アレルギー診断薬および治療薬の世界市場は、良好な発展の可能性を示しています。費用対効果の高い代替治療に対する需要の高まり、診断技術の開発、エピネフリン自動注射器などの新製品のイントロダクション、食物アレルギーの世界の発生率の上昇などがその背景にあります。

継続的な市場成長を保証するためには、医療費の高騰などの課題に取り組むことが不可欠です。アレルギー治療に対する資金調達の増加は、研究の進展と新規薬剤の利用可能性を促進しています。米国では2022年9月、アルファ・ウェーブ・ベンチャーズを主要投資家とする3,000万米ドルの資金調達ラウンドを成功裏に終了しました。

ダイナミクス

アレルゲンフリー製品に対する需要の高まり

飲食品に含まれるアレルゲンを回避する人々が世界的に増加しており、その数は約5億人、米国だけでも約8,500万人に上ります。過去20年間で、アメリカの若者の食物アレルギーの発生率は、人口増加の約4倍にまでエスカレートしています。この現象は米国に限ったことではなく、先進国、発展途上国を問わず、特に幼児の食物アレルギーが世界的に増加していることを示す証拠があります。

マッキンゼー・アンド・カンパニーの最近の調査によると、消費者は、直接アレルギーの影響を受けているにせよ、アレルギーのある人のために購入するにせよ、アレルゲンを避けるために食料品売り場を移動している間に頻繁にストレスを感じています。多くの消費者が商品ラベルの分析に多大な時間を費やしており、中には商品カテゴリー全体を敬遠する消費者さえいます。

さらに、このような消費者は、優れたアレルゲンフリー製品にプレミアムを支払うことが多く、大企業よりもアレルギーに配慮した中小企業を好むと同時に、新しい代替製品を求めています。米国では、アレルゲンフリーのスーパーマーケット製品への支出が平均を上回っており、消費者は年間190億米ドル近くを代替品やアレルゲンフリー製品に充てています。この支出は増加基調を維持すると予想され、食物アレルギーセクターの成長可能性を浮き彫りにしています。

AI主導のイノベーション

食物アレルギー業界は、人工知能（AI）技術の向上に後押しされた意識の高まりにより拡大しています。AI主導のソリューションは、正確な製品表示、成分評価、食物アレルギーを持つ個人のためのカスタマイズされた通知を通じて認知度を向上させています。この進歩により、個人は商品に含まれるアレルギーの可能性を迅速に特定できるようになり、安全で十分な情報に基づいた意思決定が容易になります。

AIを搭載したアプリケーションはラベルのスキャニングと物質の分析を容易にし、それによってアレルゲンの認識を高め、特に安全な代替食品を見つけることが困難な重度の、複数の、または珍しいアレルギーを持つ個人の食事要件を効果的に管理できるようにします。消費者向け商品に加え、ハイパースペクトル画像、機械学習、コンピュータービジョン、フーリエ変換赤外分光法を含むAI主導型技術が、アレルゲン検出のためにフードサービスや生産現場で徐々に採用されています。

非侵襲的技術は食品の品質評価と汚染物質の特定を容易にし、それによってレストランや加工施設での相互接触による重篤なアレルギー反応のリスクを軽減します。食品アレルゲンに対する認識が高まるにつれて、消費者も企業も同様に安全性と透明性を重視するようになり、食物アレルギー市場は大幅な拡大が見込まれています。

診断と投薬の高いコスト

食物アレルギー、特にピーナッツアレルギーの発見と管理に伴う多額の費用は、食物アレルギー業界にとってかなりの制約となります。調査によると、ピーナッツアレルギーは、アナフィラキシー治療に794ユーロ、アドレナリン自動注射器（AAI）処方に470ユーロの追加費用とともに、1人当たり年間304～400ユーロの医療費増に寄与しています。英国の人口の場合、これらの費用を合わせると、年間推定4,000万～5,300万ユーロになります。このような治療費は、適切な診断や継続的な治療へのアクセスを制限する可能性があります。

料金の高騰は、予防戦略、診断手順、革新的な救命治療の実施を妨げる可能性があります。十分な保険や財源のない患者は、アレルギーの検査や管理を怠り、重篤な反応を引き起こすリスクを高める可能性があります。このような制約は患者に影響を及ぼすだけでなく、食物アレルギー市場の成長も阻害します。コストの上昇は、高度な診断機器や治療法、アレルゲンフリー製品へのアクセスや需要を低下させ、市場の進展を阻害するからです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • アレルギーフリー製品の需要増加
    • AI主導のイノベーション
  • 抑制要因
    • 診断と投薬の高額な費用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• ロシア・ウクライナ戦争の影響分析
• DMIの見解

第6章 COVID-19分析

第7章 食品別

• 乳製品
• 家禽製品
• ピーナッツ
• 貝
• 小麦
• その他

第8章 診断別

• 機器
• 消耗品
• サービス
• 検査
  • In Vivo（体内）/皮膚
  • In Vitro（体外）
• その他

第9章 治療別

• エピネフリン
• 抗ヒスタミン薬
• 経口免疫療法
• その他

第10章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第13章 企業プロファイル

• Astellas Pharma, Inc.
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Aimmune Therapeutics
• Meridian Medical Technologies
• ALK-Abello Ltd
• Medeca Pharma AB
• bioMeriux SA
• Omega Diagnostics Group PLC
• HYCOR Biomedical
• HOB Biotech Group Corp Ltd.
• Cambridge Allergy Ltd

第14章 付録

Overview

Global Food Allergy Market reached US$ 40.16 billion in 2023 and is expected to reach US$ 60.19 billion by 2031, growing with a CAGR of 5.19% during the forecast period 2024-2031.

The World Allergy Organization has documented a worldwide rise in the incidence of food allergies. Eggs, milk, wheat, fish and tree nuts are among the most prevalent allergies. Notably, seafood allergies are more prevalent in Asia than to Western nations. The market growth is linked to heightened awareness, unfulfilled medical demands and the launch of novel products.

Advanced diagnostic techniques, such as refined blood assays, skin prick tests and molecular diagnostics, promote allergy identification by augmenting precision and expediency. The global market for food allergy diagnostics and therapies exhibits favorable development potential. The prospects arise from the escalating demand for cost-effective treatment alternatives, developments in diagnostic technologies, the introduction of novel products such as epinephrine auto-injectors and the rising incidence of food allergies worldwide.

It is essential to tackle challenges, such as elevated medicine expenses, to guarantee ongoing market growth. The increase in financing for allergy treatments is driving progress in research and the availability of novel medications. In September 2022, COUR Pharmaceuticals successfully concluded a funding round of US$ 30 million, including Alpha Wave Ventures as a principal investor.

Dynamics

Rising Demand for Allergen-Free Products

The global rise in individuals circumventing allergens in food and beverages-approximately 500 million, with roughly 85 million in the US alone-indicates substantial growth potential in the food allergy market. In the last twenty years, the incidence of food allergies in American youths has escalated roughly fourfold compared to population growth. This phenomenon is not limited to US; evidence suggests a global rise in food allergies, especially in young children in both developed and developing countries.

Recent research by McKinsey & Company indicates that consumers, whether directly impacted by allergies or purchasing for someone who is, frequently encounter stress while navigating grocery aisles to evade allergens. Numerous individuals invest significant time analyzing product labels, with some even eschewing entire categories of products.

Moreover, these consumers often pay a premium for superior, allergen-free products, demonstrating a preference for smaller, allergy-aware firms over larger counterparts, while also seeking new product alternatives. In US, spending on allergen-free supermarket products above the average, with consumers allocating nearly US$ 19 billion yearly to alternatives or allergen-free items. This expenditure is expected to persist in its upward trajectory, highlighting the growth potential within the food allergy sector.

AI-Driven Innovations

The food allergy industry is expanding due to heightened awareness, mostly propelled by improvements in artificial intelligence (AI) technology. AI-driven solutions are improving awareness via accurate product labeling, ingredient assessment and tailored notifications for individuals with food allergies. The advancements enable individuals to promptly identify potential allergies in items, facilitating safe and informed decision-making.

AI-powered applications facilitate the scanning of labels and the analysis of substances, thereby enhancing allergen awareness and empowering individuals to effectively manage their dietary requirements-particularly those with severe, multiple or uncommon allergies who have difficulties in locating safe food alternatives. In addition to consumer items, AI-driven technologies including hyperspectral imaging, machine learning, computer vision and Fourier transform infrared spectroscopy are progressively employed in food service and production for allergen detection.

The non-invasive techniques facilitate the assessment of food quality and the identification of pollutants, thereby mitigating the risk of severe allergic reactions due to cross-contact in restaurants and processing facilities. As awareness of food allergens escalates, the food allergy market is poised for substantial expansion, with consumers and businesses alike emphasizing safety and transparency.

High Cost Of Diagnosis And Medication

The substantial expense associated with detecting and managing food allergies, especially peanut allergies, constitutes a considerable limitation on the food allergy industry. Research indicates that peanut allergies contribute an annual incremental healthcare cost of EUR 304-400 per individual, alongside supplementary expenses of EUR 794 for anaphylaxis treatment and EUR 470 for adrenaline auto-injector (AAI) prescriptions. For UK population, these expenses together total an estimated EUR 40-53 million annually. Such fees can restrict access to adequate diagnosis and continuous treatment, as individuals and healthcare institutions may contend with these additional financial pressures.

Rising prices can impede the implementation of preventative strategies, diagnostic procedures and innovative, possibly life-saving treatments. Individuals lacking adequate insurance or financial resources may neglect allergy testing and management, heightening their risk of severe reactions. This constraint affects both patients and hinders the growth of the food allergy market, as elevated costs diminish the accessibility and demand for sophisticated diagnostic equipment, treatments and allergen-free products, hence impeding market progress.

Segment Analysis

The global food allergy market is segmented based on food sources, diagnosis, treatment, distribution channel and region.

High Risk And Treatment Focus For Peanut Allergies

Peanut allergies dominate the food source segment due to the presence of potent allergenic proteins, including Ara h 1, Ara h 2 and Ara h 3, which are known for their ability to trigger severe allergic reactions. These proteins are particularly resilient, resisting both heat and digestion, which increases the likelihood of a reaction even in trace amounts. Peanut allergy is especially dangerous, as it can cause anaphylaxis-a severe, life-threatening allergic response-often with very small exposure to the allergen, making peanuts one of the most high-risk allergens globally.

This dominance is further underscored by the fact that peanut allergy is currently the only food allergy with an FDA-approved treatment, Palforzia, highlighting the seriousness and prevalence of peanut-related reactions. Other treatments, such as peanut oral immunotherapy, are in use to increase tolerance to peanut proteins but remain non-FDA-approved. This specialized treatment focus for peanut allergies, combined with the high-risk profile of peanut proteins, positions peanuts as a leading and particularly challenging subsegment in the food allergy market..

Geographical Penetration

Advancements in North America Diagnosis and Treatment

North America is a developed region characterized by substantial healthcare expenditure. It commands the global market owing to the increasing recognition of potential in allergy therapeutics. Consequently, American corporations are allocating resources to the research and development of anti-allergenic pharmaceuticals. Furthermore, emerging competitors are launching innovative items, resulting in heightened competition among manufacturers.

The significant prevalence of food allergies in US stimulates the need for better diagnosis and effective treatment solutions. US healthcare system is a market leader, recognized for its sophisticated infrastructure, extensive access to medical services and thorough allergy testing and treatments. Advancements in treatment have significantly contributed to market growth and development. Oral immunotherapy presents significant market potential.

Recently, US Food and Drug Administration (FDA) approved Palforzia for the treatment of peanut allergy in children. This oral immunotherapy seeks to mitigate allergic responses, including anaphylaxis, resulting from inadvertent peanut exposure. It is appropriate for children between the ages of four and seventeen who have a verified diagnosis of peanut allergy.

Competitive Landscape

The major global players in the market include Astellas Pharma, Inc., Aimmune Therapeutics, Meridian Medical Technologies, ALK-Abello Ltd, Medeca Pharma AB, bioMeriux SA, Omega Diagnostics Group PLC, HYCOR Biomedical, HOB Biotech Group Corp Ltd. and Cambridge Allergy Ltd.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict has intensified the worldwide food crisis, resulting in heightened awareness and demand for allergy testing as food insecurity amplifies worries regarding the safety of accessible food. Furthermore, logistical obstacles have postponed the distribution of allergy testing kits and associated diagnostic instruments, constraining market expansion in impacted areas.

Conversely, the persistent issue has prompted an escalation in governmental and humanitarian initiatives to bolster healthcare infrastructure in impacted regions, encompassing food allergy detection. Nonetheless, healthcare systems have been overwhelmed and resources are frequently redirected to urgent humanitarian requirements, so impeding the broad availability and accessibility of allergy diagnostic services. This has led to a heterogeneous effect on market expansion, presenting constraints in certain sectors while offering development prospects in others.

Food Source

• Dairy Products
• Poultry Products
• Peanuts
• Shellfish
• Wheat
• Others

Diagnosis

• Instruments
• Consumables
• Services
• Tests
  • In Vivo/Skin
  • In Vitro
• Others

Treatment

• Epinephrine
• Antihistamines
• Oral Immunotherapy
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In March 2024, Gold Standard Diagnostics introduced the inaugural product of the new allergy PowerLine tests: the SENSIStrip Gluten PowerLine Lateral Flow Device. The device features a sensitive detection technology utilizing a monoclonal antibody to identify gluten residues in food matrices, rinse water and swabs.
• In March 2024, ALS significantly enhanced and fortified its footprint in the Life Sciences sectors of Europe and US. ALS has acquired York Analytical Laboratories, located in Northeast US and Wessling Holding GmbH & Co., based in Western Europe.
• In February 2024, Merieux NutriSciences inaugurated a state-of-the-art laboratory for food analysis in Maringa, Brazil. The newly established facility possesses federal CGRE/IMMETRO accreditation in accordance with NBR ISO/IEC 17025 standards, aimed at assisting the food industry in achieving quality benchmarks.

Why Purchase the Report?

• To visualize the global food allergy market segmentation based on food source, diagnosis, treatment, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the food allergy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global food allergy market report would provide approximately 70 tables, 68 figures and 203 pages

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Food Source
• 3.2. Snippet by Diagnosis
• 3.3. Snippet by Treatment
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Demand for Allergen-Free Products
    • 4.1.1.2. AI-Driven Innovations
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost Of Diagnosis And Medication
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Food Source

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
  • 7.1.2. Market Attractiveness Index, By Food Source
• 7.2. Dairy Products*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Poultry Products
• 7.4. Peanuts
• 7.5. Shellfish
• 7.6. Wheat
• 7.7. Others

8. By Diagnosis

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
  • 8.1.2. Market Attractiveness Index, By Diagnosis
• 8.2. Instruments*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Consumables
• 8.4. Services
• 8.5. Tests
  • 8.5.1. In Vivo/Skin
  • 8.5.2. In Vitro
• 8.6. Others

9. By Treatment

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.1.2. Market Attractiveness Index, By Treatment
• 9.2. Epinephrine*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Antihistamines
• 9.4. Oral Immunotherapy
• 9.5. Others

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospital Pharmacy*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacy
• 10.4. Online Pharmacy

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. US
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. UK
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Astellas Pharma, Inc.*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Aimmune Therapeutics
• 13.3. Meridian Medical Technologies
• 13.4. ALK-Abello Ltd
• 13.5. Medeca Pharma AB
• 13.6. bioMeriux SA
• 13.7. Omega Diagnostics Group PLC
• 13.8. HYCOR Biomedical
• 13.9. HOB Biotech Group Corp Ltd.
• 13.10. Cambridge Allergy Ltd

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us